Azenta (NASDAQ:AZTA – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17, FiscalAI reports. The firm had revenue of $167.09 million during the quarter, compared to the consensus estimate of $160.21 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.
Azenta Stock Performance
Azenta stock traded down $0.47 during mid-day trading on Tuesday, reaching $40.48. 675,892 shares of the company were exchanged, compared to its average volume of 938,985. The firm’s 50-day simple moving average is $35.48 and its two-hundred day simple moving average is $28.47. Azenta has a twelve month low of $15.93 and a twelve month high of $46.41. The firm has a market cap of $1.77 billion, a PE ratio of -14.67 and a beta of 1.47.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on AZTA shares. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 26th. Wall Street Zen cut Azenta from a “buy” rating to a “hold” rating in a research note on Sunday, October 18th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $37.00 price target on shares of Azenta in a report on Monday, September 14th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $41.20.
Read Our Latest Report on Azenta
About Azenta
Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.
Read More
- Five stocks we like better than Azenta
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
